Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Real-Time Tracking for Jets Near, Rockwell Collins Says
18:04 - March 3 -- Kelly Ortberg, chief executive officer of Rockwell Collins Inc., talks about the market outlook for the aerospace supplier, the impact of the U.S. dollar, euro and cheaper oil on business, and plans to unveil technology that would enable airlines to continuously and inexpensively track jetliners in real time. Ortberg also discusses connectivity for airline passengers and crew members. He speaks with Mark Crumpton on Bloomberg Television's "Bottom Line."
  • Live From Beijing...It's Saturday Night!
  • Vote of Confidence for Lumber Liquidators
  • House Passes DHS Funds